With the March 2026 patent expiry for semaglutide, over 20 Indian firms have launched generic versions. This has rapidly lowered treatment costs for diabetes and obesity, creating a potential billion-dollar market opportunity for domestic pharmaceutical manufacturers.
The expiration of the primary patent for semaglutide on March 20, 2026, has triggered a major shift in India's metabolic healthcare market. Domestic pharmaceutical companies are quickly launching affordable generic versions of GLP-1 receptor agonists, a class of drugs used for managing type 2 diabetes, obesity, and related metabolic conditions. This move is making advanced therapies significantly more accessible to patients by lowering costs compared to the original innovator products.
Competitive Landscape and Market Share
Recent data indicates that Torrent Pharmaceuticals has established a strong initial lead in this segment, capturing approximately 38% of the generic semaglutide market. Eris Lifesciences has also secured a significant position, holding about 22% of the market share by volume and 13% to 14% by value during the first quarter following the patent expiry. The rapid entry of more than 20 players into the generic space has intensified competition, leading to a meaningful reduction in retail prices for these treatments.
Financial Impact and Market Size
The monthly sales for generic semaglutide in India are currently estimated at around ₹30 crore, translating to an annual run rate of approximately ₹360 crore. When including the broader GLP-1 therapy market, which encompasses other treatments like tirzepatide, the annual market size in India is estimated at ₹1,906 crore. Industry projections suggest this segment could grow beyond $1 billion over the next few years as awareness rises and clinical adoption increases for both diabetes and weight management indications.
Manufacturing and Operational Challenges
Unlike traditional oral medicines, manufacturing injectable GLP-1 therapies involves high technical complexity. This difficulty acts as a barrier to entry, naturally consolidating the market among companies with advanced infrastructure. To maintain profitability and secure supply chains, firms like Eris Lifesciences are investing in backward integration. This includes developing in-house capabilities for synthetic semaglutide and recombinant technology, which helps in scaling production while managing long-term costs.
Clinical and Regulatory Considerations
While the market opportunity is significant, these drugs are potent clinical agents that modify disease pathways rather than just treating symptoms. They are currently viewed as complementary to traditional treatments like insulin rather than direct replacements. As these therapies gain traction, the key monitorable for investors will be how companies manage manufacturing margins amidst intense pricing competition. Sustained success will likely depend on a company’s ability to maintain high quality-control standards, secure clinical adoption, and manage the costs associated with complex injectable manufacturing processes.